CN114317454B - 一种鼠抗oxa-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 - Google Patents
一种鼠抗oxa-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 Download PDFInfo
- Publication number
- CN114317454B CN114317454B CN202210189253.2A CN202210189253A CN114317454B CN 114317454 B CN114317454 B CN 114317454B CN 202210189253 A CN202210189253 A CN 202210189253A CN 114317454 B CN114317454 B CN 114317454B
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- oxa
- carbapenemase
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010068385 carbapenemase Proteins 0.000 title claims abstract description 68
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 14
- 238000000338 in vitro Methods 0.000 claims abstract description 8
- 238000003745 diagnosis Methods 0.000 claims abstract description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 25
- 238000004321 preservation Methods 0.000 claims description 19
- 241001529936 Murinae Species 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000011156 evaluation Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000009897 systematic effect Effects 0.000 abstract description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 abstract description 2
- 238000003757 reverse transcription PCR Methods 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000001514 detection method Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 238000005406 washing Methods 0.000 description 11
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 3
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 2
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- GPISLLFQNHELLK-DCAQKATOSA-N Gln-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N GPISLLFQNHELLK-DCAQKATOSA-N 0.000 description 2
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 2
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- RAGOJJCBGXARPO-XVSYOHENSA-N Phe-Thr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 RAGOJJCBGXARPO-XVSYOHENSA-N 0.000 description 2
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 2
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 2
- KIEIJCFVGZCUAS-MELADBBJSA-N Ser-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N)C(=O)O KIEIJCFVGZCUAS-MELADBBJSA-N 0.000 description 2
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 2
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- CDRYEAWHKJSGAF-BPNCWPANSA-N Tyr-Ala-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O CDRYEAWHKJSGAF-BPNCWPANSA-N 0.000 description 2
- XYNFFTNEQDWZNY-ULQDDVLXSA-N Tyr-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N XYNFFTNEQDWZNY-ULQDDVLXSA-N 0.000 description 2
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 108010068265 aspartyltyrosine Proteins 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- SSSROGPPPVTHLX-FXQIFTODSA-N Ala-Arg-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSROGPPPVTHLX-FXQIFTODSA-N 0.000 description 1
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 1
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 1
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 1
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 1
- JEXPNDORFYHJTM-IHRRRGAJSA-N Arg-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCN=C(N)N JEXPNDORFYHJTM-IHRRRGAJSA-N 0.000 description 1
- JEOCWTUOMKEEMF-RHYQMDGZSA-N Arg-Leu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEOCWTUOMKEEMF-RHYQMDGZSA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- XSPKAHFVDKRGRL-DCAQKATOSA-N Arg-Pro-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XSPKAHFVDKRGRL-DCAQKATOSA-N 0.000 description 1
- WQSCVMQDZYTFQU-FXQIFTODSA-N Asn-Cys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WQSCVMQDZYTFQU-FXQIFTODSA-N 0.000 description 1
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 1
- JZDZLBJVYWIIQU-AVGNSLFASA-N Asn-Glu-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JZDZLBJVYWIIQU-AVGNSLFASA-N 0.000 description 1
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 1
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
- YSYTWUMRHSFODC-QWRGUYRKSA-N Asn-Tyr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O YSYTWUMRHSFODC-QWRGUYRKSA-N 0.000 description 1
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- RSMZEHCMIOKNMW-GSSVUCPTSA-N Asp-Thr-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RSMZEHCMIOKNMW-GSSVUCPTSA-N 0.000 description 1
- KACWACLNYLSVCA-VHWLVUOQSA-N Asp-Trp-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KACWACLNYLSVCA-VHWLVUOQSA-N 0.000 description 1
- AWPWHMVCSISSQK-QWRGUYRKSA-N Asp-Tyr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O AWPWHMVCSISSQK-QWRGUYRKSA-N 0.000 description 1
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- RGXXLQWXBFNXTG-CIUDSAMLSA-N Gln-Arg-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O RGXXLQWXBFNXTG-CIUDSAMLSA-N 0.000 description 1
- DLOHWQXXGMEZDW-CIUDSAMLSA-N Gln-Arg-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O DLOHWQXXGMEZDW-CIUDSAMLSA-N 0.000 description 1
- IPHGBVYWRKCGKG-FXQIFTODSA-N Gln-Cys-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O IPHGBVYWRKCGKG-FXQIFTODSA-N 0.000 description 1
- PODFFOWWLUPNMN-DCAQKATOSA-N Gln-His-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PODFFOWWLUPNMN-DCAQKATOSA-N 0.000 description 1
- KQOPMGBHNQBCEL-HVTMNAMFSA-N Gln-His-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KQOPMGBHNQBCEL-HVTMNAMFSA-N 0.000 description 1
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 1
- XZLLTYBONVKGLO-SDDRHHMPSA-N Gln-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XZLLTYBONVKGLO-SDDRHHMPSA-N 0.000 description 1
- LHMWTCWZARHLPV-CIUDSAMLSA-N Gln-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N LHMWTCWZARHLPV-CIUDSAMLSA-N 0.000 description 1
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 1
- KRRFFAHEAOCBCQ-SIUGBPQLSA-N Glu-Ile-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KRRFFAHEAOCBCQ-SIUGBPQLSA-N 0.000 description 1
- IOUQWHIEQYQVFD-JYJNAYRXSA-N Glu-Leu-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IOUQWHIEQYQVFD-JYJNAYRXSA-N 0.000 description 1
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
- MFNUFCFRAZPJFW-JYJNAYRXSA-N Glu-Lys-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFNUFCFRAZPJFW-JYJNAYRXSA-N 0.000 description 1
- FMBWLLMUPXTXFC-SDDRHHMPSA-N Glu-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)N)C(=O)O FMBWLLMUPXTXFC-SDDRHHMPSA-N 0.000 description 1
- HVKAAUOFFTUSAA-XDTLVQLUSA-N Glu-Tyr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O HVKAAUOFFTUSAA-XDTLVQLUSA-N 0.000 description 1
- KXRORHJIRAOQPG-SOUVJXGZSA-N Glu-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O KXRORHJIRAOQPG-SOUVJXGZSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 1
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 1
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 1
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 1
- IEGFSKKANYKBDU-QWHCGFSZSA-N Gly-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)O IEGFSKKANYKBDU-QWHCGFSZSA-N 0.000 description 1
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 1
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- UMRIXLHPZZIOML-OALUTQOASA-N Gly-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CN UMRIXLHPZZIOML-OALUTQOASA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- GVEODXUBBFDBPW-MGHWNKPDSA-N Ile-Tyr-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 GVEODXUBBFDBPW-MGHWNKPDSA-N 0.000 description 1
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- OXKYZSRZKBTVEY-ZPFDUUQYSA-N Leu-Asn-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OXKYZSRZKBTVEY-ZPFDUUQYSA-N 0.000 description 1
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 1
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 1
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 1
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 description 1
- MEQLGHAMAUPOSJ-DCAQKATOSA-N Lys-Ser-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O MEQLGHAMAUPOSJ-DCAQKATOSA-N 0.000 description 1
- WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- WRXOPYNEKGZWAZ-FXQIFTODSA-N Met-Ser-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O WRXOPYNEKGZWAZ-FXQIFTODSA-N 0.000 description 1
- MNGBICITWAPGAS-BPUTZDHNSA-N Met-Ser-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O MNGBICITWAPGAS-BPUTZDHNSA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- DFEVBOYEUQJGER-JURCDPSOSA-N Phe-Ala-Ile Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O DFEVBOYEUQJGER-JURCDPSOSA-N 0.000 description 1
- OPEVYHFJXLCCRT-AVGNSLFASA-N Phe-Gln-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O OPEVYHFJXLCCRT-AVGNSLFASA-N 0.000 description 1
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 1
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 1
- BPIMVBKDLSBKIJ-FCLVOEFKSA-N Phe-Thr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BPIMVBKDLSBKIJ-FCLVOEFKSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- VOZIBWWZSBIXQN-SRVKXCTJSA-N Pro-Glu-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O VOZIBWWZSBIXQN-SRVKXCTJSA-N 0.000 description 1
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 1
- FIDNSJUXESUDOV-JYJNAYRXSA-N Pro-Tyr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O FIDNSJUXESUDOV-JYJNAYRXSA-N 0.000 description 1
- IMNVAOPEMFDAQD-NHCYSSNCSA-N Pro-Val-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IMNVAOPEMFDAQD-NHCYSSNCSA-N 0.000 description 1
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- ICHZYBVODUVUKN-SRVKXCTJSA-N Ser-Asn-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ICHZYBVODUVUKN-SRVKXCTJSA-N 0.000 description 1
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 1
- KCFKKAQKRZBWJB-ZLUOBGJFSA-N Ser-Cys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O KCFKKAQKRZBWJB-ZLUOBGJFSA-N 0.000 description 1
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 description 1
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- GFDUZZACIWNMPE-KZVJFYERSA-N Thr-Ala-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O GFDUZZACIWNMPE-KZVJFYERSA-N 0.000 description 1
- PZSDPRBZINDEJV-HTUGSXCWSA-N Thr-Phe-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PZSDPRBZINDEJV-HTUGSXCWSA-N 0.000 description 1
- NZRUWPIYECBYRK-HTUGSXCWSA-N Thr-Phe-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O NZRUWPIYECBYRK-HTUGSXCWSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
- LXXCHJKHJYRMIY-FQPOAREZSA-N Thr-Tyr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O LXXCHJKHJYRMIY-FQPOAREZSA-N 0.000 description 1
- ABCLYRRGTZNIFU-BWAGICSOSA-N Thr-Tyr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O ABCLYRRGTZNIFU-BWAGICSOSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- NAQBQJOGGYGCOT-QEJZJMRPSA-N Trp-Asn-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O NAQBQJOGGYGCOT-QEJZJMRPSA-N 0.000 description 1
- BGWSLEYVITZIQP-DCPHZVHLSA-N Trp-Phe-Ala Chemical compound C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(O)=O BGWSLEYVITZIQP-DCPHZVHLSA-N 0.000 description 1
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 1
- UGFOSENEZHEQKX-PJODQICGSA-N Trp-Val-Ala Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(O)=O UGFOSENEZHEQKX-PJODQICGSA-N 0.000 description 1
- UOXPLPBMEPLZBW-WDSOQIARSA-N Trp-Val-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 UOXPLPBMEPLZBW-WDSOQIARSA-N 0.000 description 1
- HSVPZJLMPLMPOX-BPNCWPANSA-N Tyr-Arg-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O HSVPZJLMPLMPOX-BPNCWPANSA-N 0.000 description 1
- SMLCYZYQFRTLCO-UWJYBYFXSA-N Tyr-Cys-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O SMLCYZYQFRTLCO-UWJYBYFXSA-N 0.000 description 1
- AZGZDDNKFFUDEH-QWRGUYRKSA-N Tyr-Gly-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AZGZDDNKFFUDEH-QWRGUYRKSA-N 0.000 description 1
- YIKDYZDNRCNFQB-KKUMJFAQSA-N Tyr-His-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O YIKDYZDNRCNFQB-KKUMJFAQSA-N 0.000 description 1
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 1
- SZEIFUXUTBBQFQ-STQMWFEESA-N Tyr-Pro-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SZEIFUXUTBBQFQ-STQMWFEESA-N 0.000 description 1
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 1
- VKYDVKAKGDNZED-STECZYCISA-N Tyr-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N VKYDVKAKGDNZED-STECZYCISA-N 0.000 description 1
- ABSXSJZNRAQDDI-KJEVXHAQSA-N Tyr-Val-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ABSXSJZNRAQDDI-KJEVXHAQSA-N 0.000 description 1
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 1
- OVBMCNDKCWAXMZ-NAKRPEOUSA-N Val-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N OVBMCNDKCWAXMZ-NAKRPEOUSA-N 0.000 description 1
- RQOMPQGUGBILAG-AVGNSLFASA-N Val-Met-Leu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O RQOMPQGUGBILAG-AVGNSLFASA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- UJMCYJKPDFQLHX-XGEHTFHBSA-N Val-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N)O UJMCYJKPDFQLHX-XGEHTFHBSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- PGBMPFKFKXYROZ-UFYCRDLUSA-N Val-Tyr-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N PGBMPFKFKXYROZ-UFYCRDLUSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明提供鼠抗OXA‑48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用，通过小鼠杂交瘤单克隆抗体筛选及RT‑PCR法克隆Ig可变区基因，获得稳定分泌鼠抗OXA‑48型碳青霉烯酶抗体的杂交瘤细胞株及其可变区序列；通过系统性评价，鼠抗OXA‑48型碳青霉烯酶抗体在各方面均有较佳表现，效价达到了1:1280000以上，适合作为免疫诊断试剂用于制备碳青霉烯酶耐药菌株体外诊断试剂盒。
Description
技术领域
本发明属于抗体制备技术领域，尤其是涉及一种鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用。
背景技术
碳青霉烯酶是一种β-内酰胺酶，有较高的水解碳青霉烯类抗生素的能力，按Ambler 分子结构分为A 类、B 类和D 类三类酶，A 类酶包括KPC，B 类酶包括NDM、IMP、VIM和GIM 等，D 类酶有OXA 等，其中OXA-48 型酶在碳青霉烯类耐药中显示出愈来愈重要的作用，在全球各地关于其在肠杆菌科耐药的报道日渐增多。2001 年Poirel L等发现了一种新型的β-内酰胺酶基因，即blaOXA-48 基因，该基因在一株几乎对所有β-内酰胺类药物耐药的肺炎克雷伯菌中发现。自OXA-48被发现以来，过去10余年中，产OXA-48 细菌在地中海地区的检出率不断增加，成为主要流行地区，随后OXA-48 在墨西哥、利比亚、埃及、突尼斯和印度等国家相继被报道，近几年，在美国和中国台湾也陆续出现。
实验室检测碳青霉烯酶的方法众多，主要包括改良Hodge试验、Carba NP试验、改良碳青霉烯灭活试验（modified carbapenem inactivation method，mCIM）、酶抑制剂增强试验、免疫金标试验以及分子生物学方法等。免疫诊断试剂是体外诊断试剂中发展最快的细分领域，利用抗原与抗体之间的特异性结合进行定性或定量检测。研发具有自主知识产权的碳青霉烯酶快速诊断产品对于耐药菌株的早期分型、指导用药，提高我国的医疗卫生水平具有重要意义。
发明内容
为解决上述技术问题，本发明提供一种鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用。
本发明采用的技术方案是：一种鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株，命名为IB5，保藏编号为CGMCC No.20284；或者命名为IH3，保藏编号为CGMCC No.20283。
一种鼠抗OXA-48型碳青霉烯酶抗体，抗体IB5，包括轻链可变区和重链可变区，轻链可变区包括如SEQ ID NO:1所示的CDRL1、SEQ ID NO:2所示的CDRL2和SEQ ID NO:3所示的CDRL3，重链可变区包括如SEQ ID NO:4所示的CDRH1、SEQ ID NO:5所示的CDRH2和SEQ IDNO:6所示的CDRH3；
SEQ ID NO:1 RASKSISKYLA（CDRL1）
SEQ ID NO:2 SGSTFQS（CDRL2）
SEQ ID NO:3 QQHNEYPYVT（CDRL3）
SEQ ID NO:4 GFTFSTYAMS（CDRH1）
SEQ ID NO:5 TISSGGSYTSYPDSVKG（CDRH2）
SEQ ID NO:6 RPEYAMDY（CDRH3）
或者，
抗体IH3，轻链可变区包括如SEQ ID NO:11所示的CDRL1、SEQ ID NO:12所示的CDRL2和SEQ ID NO:13所示的CDRL3，重链可变区包括如SEQ ID NO:14所示的CDRH1、SEQ IDNO:15所示的CDRH2和SEQ ID NO:16所示的CDRH3；
SEQ ID NO:11 RASKSVSTSGYSYMH（CDRL1）
SEQ ID NO:12 LVSNLES（CDRL2）
SEQ ID NO:13 QHIRELYT（CDRL3）
SEQ ID NO:14 GYTFTDYVIS（CDRH1）
SEQ ID NO:15 EIYPGSDTTYHNEKFKG（CDRH2）
SEQ ID NO:16 DYGSNYGWFAY（CDRH3）
优选地，抗体IB5轻链可变区氨基酸序列为SEQ ID NO:7所示，重链可变区氨基酸序列为SEQ ID NO:9所示；
SEQ ID NO:7
DWIQLVQHQPVSSYLAASPGETVTINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTFQSGFPSGFSGSGSGTDFTLTVSSLEPEDFAIYYCQQHNEYPYVTFGGGTKLEIKRA
SEQ ID NO:9
QCEVMLVESGGGLVKPGGSLKLSCAASGFTFSTYAMSWVRLTPEKRLEWVATISSGGSYTSYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARRPEYAMDYWGQGTSVTVSSA
抗体IH3轻链可变区氨基酸序列为SEQ ID NO:17所示，重链可变区氨基酸序列为SEQ ID NO:19所示；
SEQ ID NO:17
DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELYTFGGGTKLEIK
SEQ ID NO:19
EVKLQQSGPELVKPGASVKMSCMASGYTFTDYVISWVKQRNGQGLEWIGEIYPGSDTTYHNEKFKGKATLTADISSNTVYMQLSSLTFEDSAVYFCARDYGSNYGWFAYWGQGTLVTVSA
优选地，抗体IB5由保藏编号为CGMCC No.20284的鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株产生；
抗体IH3由保藏编号为CGMCC No.20283的鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株产生。
一种核酸分子，包含编码鼠抗OXA-48型碳青霉烯酶抗体的核苷酸。
优选地，所述核酸分子编码抗体IB5的轻链可变区的核苷酸序列如SEQ ID NO:8所示，所述核酸分子编码抗体IB5的重链可变区的核苷酸序列如SEQ ID NO:10所示；
SEQ ID NO:8
GATTGGATACAGTTGGTGCAGCATCAGCCCGTTTCATCTTATCTTGCTGCATCTCCTGGAGAAACCGTTACTATTAATTGCAGGGCAAGTAAGAGCATTAGCAAGTATTTAGCCTGGTATCAAGAGAAACCTGGGAAAACTAATAAGCTTCTTATCTACTCTGGTTCCACTTTCCAATCTGGATTTCCATCAGGGTTCAGTGGCAGTGGATCTGGTACAGATTTCACTCTCACCGTCAGTAGCCTGGAGCCTGAAGACTTTGCAATCTATTACTGTCAACAGCATAATGAGTACCCGTACGTCACGTTCGGAGGGGGGACCAAGCTGGAGATAAAACGGGCT
SEQ ID NO:10
CAGTGTGAAGTGATGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTACCTATGCCATGTCTTGGGTTCGCCTGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACCATTAGTAGTGGTGGTAGTTACACCTCCTATCCAGACAGTGTGAAGGGGCGCTTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACTGTGCACGACGACCCGAATATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCC
所述核酸分子编码抗体IH3的轻链可变区的核苷酸序列如SEQ ID NO:18所示，所述核酸分子编码抗体IH3的重链可变区的核苷酸序列如SEQ ID NO:20所示；
SEQ ID NO:18
GACATTGTGCTGACACAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATCTATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGTCAGCACATTAGGGAGCTTTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
SEQ ID NO:20
GAGGTGAAGCTGCAGCAGTCTGGACCTGAGTTGGTGAAGCCTGGGGCTTCAGTGAAGATGTCCTGCATGGCTTCTGGATACACATTCACTGACTATGTTATAAGTTGGGTGAAGCAGAGAAATGGACAGGGCCTTGAGTGGATTGGAGAGATTTATCCTGGAAGTGATACCACTTACCACAATGAGAAATTCAAGGGCAAGGCCACACTGACTGCAGACATATCCTCCAACACAGTCTACATGCAGCTCAGTAGTCTGACATTTGAGGATTCTGCGGTCTATTTCTGTGCAAGAGACTACGGTAGTAACTACGGCTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA
鼠抗OXA-48型碳青霉烯酶抗体在制备检测OXA-48型碳青霉烯酶抗原试剂中的应用。
优选地，将鼠抗OXA-48型碳青霉烯酶抗体用于制备体外诊断试剂盒或微流体芯片，所述体外诊断试剂盒为胶体金免疫试剂盒、化学发光试剂盒、放射免疫试剂盒、酶联免疫试剂盒或荧光免疫试剂盒。
优选地，制备双抗体夹心法免疫胶体金试纸条，抗体IB5为包被抗体，抗体IH3为金标抗体；
或者，抗体IH3为包被抗体，抗体IB5为金标抗体。
本发明具有的优点和积极效果是：本发明提供两种鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株，分别能够产生两种鼠抗OXA-48型碳青霉烯酶抗体；通过系统性评价，包括对抗体亚型及效价、试剂盒灵敏度、特异性和稳定性的评价，鼠抗OXA-48型碳青霉烯酶单克隆抗体在各方面均有较佳表现，效价达到了1:1280000以上，从而适合作为免疫诊断试剂用于制备碳青霉烯酶耐药菌株体外诊断试剂盒。
附图说明
图1是鼠抗OXA-48型碳青霉烯酶蛋白电泳图；
图2是鼠抗OXA-48型碳青霉烯酶抗体蛋白电泳图；
图3是胶体金法鼠抗OXA-48型碳青霉烯酶检测卡检测结果。
生物材料：IB5，保藏日期为2020年8月27日，保藏单位为中国微生物菌种保藏管理委员会普通微生物中心（CGMCC），保藏编号是CGMCC No.20284；
生物材料：IH3，保藏日期为2020年8月27日，保藏单位为中国微生物菌种保藏管理委员会普通微生物中心（CGMCC），保藏编号是CGMCC No.20283。
具体实施方式
下面对本发明的实施例做出说明。
本发明涉及鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株，生物材料命名为IB5，属杂交瘤细胞，其保藏编号是CGMCC No. 20284；保藏地为中国微生物菌种保藏管理委员会普通微生物中心，其保藏日期为2020年8月27日，检测为存活。另有一株鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株，生物材料命名为IH3，属杂交瘤细胞，其保藏编号是CGMCC No.20283；保藏地为中国微生物菌种保藏管理委员会普通微生物中心，其保藏日期为2020年8月27日，检测为存活。
鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株生产得到的抗体IB5，包括轻链可变区和重链可变区，轻链可变区包括如SEQ ID NO:1所示的CDRL1、SEQ ID NO:2所示的CDRL2和SEQID NO:3所示的CDRL3，重链可变区包括如SEQ ID NO:4所示的CDRH1、SEQ ID NO:5所示的CDRH2和SEQ ID NO:6所示的CDRH3；
SEQ ID NO:1 RASKSISKYLA（CDRL1）
SEQ ID NO:2 SGSTFQS（CDRL2）
SEQ ID NO:3 QQHNEYPYVT（CDRL3）
SEQ ID NO:4 GFTFSTYAMS（CDRH1）
SEQ ID NO:5 TISSGGSYTSYPDSVKG（CDRH2）
SEQ ID NO:6 RPEYAMDY（CDRH3）；
抗体IB5轻链可变区氨基酸序列为SEQ ID NO:7所示，重链可变区氨基酸序列为SEQ ID NO:9所示；
SEQ ID NO:7
DWIQLVQHQPVSSYLAASPGETVTINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTFQSGFPSGFSGSGSGTDFTLTVSSLEPEDFAIYYCQQHNEYPYVTFGGGTKLEIKRA
SEQ ID NO:9
QCEVMLVESGGGLVKPGGSLKLSCAASGFTFSTYAMSWVRLTPEKRLEWVATISSGGSYTSYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARRPEYAMDYWGQGTSVTVSSA；
编码抗体IB5的轻链可变区的核苷酸序列如SEQ ID NO:8所示，编码抗体IB5的重链可变区的核苷酸序列如SEQ ID NO:10所示；
SEQ ID NO:8
GATTGGATACAGTTGGTGCAGCATCAGCCCGTTTCATCTTATCTTGCTGCATCTCCTGGAGAAACCGTTACTATTAATTGCAGGGCAAGTAAGAGCATTAGCAAGTATTTAGCCTGGTATCAAGAGAAACCTGGGAAAACTAATAAGCTTCTTATCTACTCTGGTTCCACTTTCCAATCTGGATTTCCATCAGGGTTCAGTGGCAGTGGATCTGGTACAGATTTCACTCTCACCGTCAGTAGCCTGGAGCCTGAAGACTTTGCAATCTATTACTGTCAACAGCATAATGAGTACCCGTACGTCACGTTCGGAGGGGGGACCAAGCTGGAGATAAAACGGGCT
SEQ ID NO:10
CAGTGTGAAGTGATGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTACCTATGCCATGTCTTGGGTTCGCCTGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACCATTAGTAGTGGTGGTAGTTACACCTCCTATCCAGACAGTGTGAAGGGGCGCTTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACTGTGCACGACGACCCGAATATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCC；
鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株生产得到的抗体IH3，轻链可变区包括如SEQ ID NO:11所示的CDRL1、SEQ ID NO:12所示的CDRL2和SEQ ID NO:13所示的CDRL3，重链可变区包括如SEQ ID NO:14所示的CDRH1、SEQ ID NO:15所示的CDRH2和SEQ ID NO:16所示的CDRH3；
SEQ ID NO:11 RASKSVSTSGYSYMH（CDRL1）
SEQ ID NO:12 LVSNLES（CDRL2）
SEQ ID NO:13 QHIRELYT（CDRL3）
SEQ ID NO:14GYTFTDYVIS（CDRH1）
SEQ ID NO:15EIYPGSDTTYHNEKFKG（CDRH2）
SEQ ID NO:16DYGSNYGWFAY（CDRH3）。
抗体IH3轻链可变区氨基酸序列为SEQ ID NO:17所示，重链可变区氨基酸序列为SEQ ID NO:19所示；
SEQ ID NO:17
DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELYTFGGGTKLEIK
SEQ ID NO:19
EVKLQQSGPELVKPGASVKMSCMASGYTFTDYVISWVKQRNGQGLEWIGEIYPGSDTTYHNEKFKGKATLTADISSNTVYMQLSSLTFEDSAVYFCARDYGSNYGWFAYWGQGTLVTVSA。
编码抗体IH3的轻链可变区的核苷酸序列如SEQ ID NO:18所示，编码抗体IH3的重链可变区的核苷酸序列如SEQ ID NO:20所示；
SEQ ID NO:18
GACATTGTGCTGACACAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATCTATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGTCAGCACATTAGGGAGCTTTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
SEQ ID NO:20
GAGGTGAAGCTGCAGCAGTCTGGACCTGAGTTGGTGAAGCCTGGGGCTTCAGTGAAGATGTCCTGCATGGCTTCTGGATACACATTCACTGACTATGTTATAAGTTGGGTGAAGCAGAGAAATGGACAGGGCCTTGAGTGGATTGGAGAGATTTATCCTGGAAGTGATACCACTTACCACAATGAGAAATTCAAGGGCAAGGCCACACTGACTGCAGACATATCCTCCAACACAGTCTACATGCAGCTCAGTAGTCTGACATTTGAGGATTCTGCGGTCTATTTCTGTGCAAGAGACTACGGTAGTAACTACGGCTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA。
抗OXA-48型碳青霉烯酶单克隆抗体通过系统性评价，包括对抗体亚型及效价、试剂盒灵敏度、特异性和稳定性的评价，抗OXA-48型碳青霉烯酶单克隆抗体在各方面均有较佳表现，从而适合作为免疫诊断试剂用于制备体外诊断试剂盒。可以制作成胶体金免疫试剂盒、化学发光试剂盒、放射免疫试剂盒、酶联免疫试剂盒或荧光免疫试剂盒，或者制作为微流体芯片；制作的试剂盒能够检测OXA-48型碳青霉烯酶抗原。本方案所涉及的两种抗体尤其适合搭配制成双抗体夹心法免疫胶体金试纸条，其中抗体IB5为包被抗体，抗体IH3为金标抗体，制得的双抗体夹心法免疫胶体金试纸条灵敏性更高，同时，也可将抗体IB5做为金标抗体，抗体IH3为包被抗体。下面通过具体实施例对本发明做出进一步说明。其中，未具体说明操作步骤的实验方法，均按照相应商品说明书进行，实施例中所用到的仪器、试剂、耗材如无特殊说明，均可从商业公司购买得到。
实施例1：鼠抗OXA-48型碳青霉烯酶单克隆抗体的制备
1.1 抗原表达
获得重组质粒：将OXA-48型基因序列构建到Pet-28a(+) 载体上并进行全基因合成。
转化到宿主菌：将含有目的基因的载体Pet-28a(+)转化到克隆宿主大肠杆菌。
扩大培养：将验证正确的转化子进行扩大培养，并转接到含有卡那霉素抗性的LB液体培养基中，37℃摇床震荡培养。
诱导：当菌液OD值在0.4~0.6 之间时，加入IPTG 终浓度为0.1mM，30℃培养4小时，离心收集菌体。
超声破碎菌体：约1g 加入30mL PBS 重悬菌体后超声破碎，功率为400 W，超声3s，间隔5 s，约30分钟后，菌液不黏稠且澄清后，离心去掉菌体碎片，上清过0.45 μm滤膜。
纯化：将上清液过镍柱纯化后，透析到PBS中，获得纯度较高目的蛋白，分子量和预计30.7.kD相符，SDS-PAGE见图1，用BCA法定量后分装进行后续实验。
1.2 小鼠免疫
用纯化的OXA-48型碳青霉烯酶免疫6周龄左右的雌性Balb/c小鼠，进行抗体制备，蛋白含量为0.1mg/ml，按照免疫剂量分为2组，每组5只小鼠；按照抗原含量计算，第一组免疫剂量为25ug/只，第二组免疫剂量为50ug/只，首免，取适量OXA-48型碳青霉烯酶经蒸馏水稀释至300ul，加入等量弗氏完全佐剂300ul乳化均匀，皮下多点注射免疫小鼠；两周后，取相同剂量进行二免，二免为腹腔注射免疫小鼠，两周后再追加免疫一次，亦为腹腔注射免疫小鼠，7天后鼠尾采血，ELISA测定小鼠血清效价。
具体步骤为：OXA-48 0.2ug/ml，100ul/孔，4℃过夜包被ELISA板，甩干，PBST洗涤3次。5%脱脂乳粉，200ul/孔，37度封闭2h。小鼠鼠尾采血，3000转/min，离心后收集血清，从1:1000开始用PBS进行倍比稀释至1:512000，备用。甩干，PBST洗涤3次，1:1000倍起加入PBS稀释的一抗，100ul/孔，37度，1h。甩干，PBST洗涤3次，加 PBS 1:6000倍稀释的羊抗鼠二抗，100ul/孔，37度，45min。甩干，PBST洗涤5次，加100ulTMB/孔，37℃，显色10min，终止，读值。
1.3 细胞融合
融合前三天进行小鼠加强免疫，接种量同前次免疫，不加佐剂，腹腔注射。融合前一天准备饲养层细胞，取6-8周龄小鼠Balb/c 1只，取眼球放血后颈椎脱位致死，放于75％酒精中消毒5min，固定于盘上，在超净台中无菌剪开腹部皮肤。用无菌注射器吸取HAT选择培养液10ml注入小鼠腹腔，用酒精棉球轻揉腹部，抽回培养基。加入40ml HAT培养液中，铺入到4块96孔细胞培养板中，100μL/ 孔，37℃，5％CO2细胞培养箱中培养。融合前一周复苏骨髓瘤细胞（Sp2/0细胞），用含10%胎牛血清的PRMI-1640培养基培养，37℃，5％CO2培养箱中传代培养。将处于对数生长期的细胞收集至离心管中，细胞计数，把细胞稀释为107个/ml备用。取加强免疫3天的Balb/c小鼠，摘眼球放血制备阳性血清，脱颈椎处死，75％酒精消毒5min，在超净工作台无菌取出脾脏，在无菌平皿中冼涤数次，剥离结缔组织。将脾脏放在微孔铜网上，加入新鲜的RPMI-1640培养液，先用注射器吸取培养液由脾脏一段注入，吹下脾细胞，反复数次之后，用注射器的内塞轻轻将剩余脾脏研磨，直到无明显的红色组织块。将平皿中脾细胞悬液轻轻吹打后转移到50ml离心管中，1000r/min离心5min，收集脾细胞，计数后备用。将免疫鼠脾细胞与Sp2/0细胞按细胞数量10:1混合，加入50ml的离心管内，1000r/min离心5min，弃上清，在手心轻轻摩擦使两种细胞充分混匀，将离心管至于100mL蓝盖瓶内，蓝盖瓶内装有37℃热水，将预热好的1ml DMSO/PEG在1min内逐滴加入融合管内，先慢后快，边加边轻轻旋转离心管。然后立即加入无抗无血RPMI-1640培养液终止反应，第一分钟加1ml，第二分钟加2ml，第三分钟加3ml，第四分钟加4ml。37℃水浴5min，后800r/min离心5min，弃上清，将沉淀以HAT悬起，混匀到40ml含37℃预热的20％小牛血清的HAT选择培养液中，铺入已加有饲养细胞的96孔细胞板中，100μL/孔，将培养板放入37℃，5％CO2培养箱培养。7d后将用新鲜的HAT培养基对细胞板半换液，10天后用HT培养基全换液。将96孔板中检测阳性的细胞采用有限稀释法进行亚克隆：首先按照上述方法制备饲养层细胞，取待克隆杂交瘤细胞进行细胞计数，用HT培养基将细胞稀释至5-8个细胞/ml，加入到已铺饲养细胞的96孔细胞板中100μL/孔，每株杂交瘤细胞克隆一块96孔细胞板，37℃、5％CO2细胞培养箱中培养。约5天后数出细胞孔里的克隆数，标记，7天时并换新的培养基，待细胞铺满整个孔底的1/3～1/2时检测。经过2-3次克隆化，待96孔板所有细胞孔均为阳性时，即可进行扩大培养，定株，冻存。将检测阳性确定定株的杂交瘤细胞扩大培养并冻存。具体过程如下：将生长旺盛、状态良好的杂交瘤细胞用无抗无血DMEM轻轻从细胞瓶上吹下，1000 r/min离心5min，弃去上清。加入冻存液（含40%RPMI-1640培养液、50%胎牛血清、10%DMSO），将细胞吹散后分装到细胞冻存管中。将冻存管放入冻存盒置于-70℃冰箱中，一天后将冻存管转移入液氮中，做好记录。
1.4 腹水制备
取10-12周龄雌性Balb/c小鼠，腹腔注射无菌液体石蜡，0.5mL/只，7d后腹腔注射培养至对数期的杂交瘤细胞，5×106个细胞/只。每天注意观察，约7-10天，待小鼠腹部出现明显隆起后，用75％酒精棉球消毒下腹部皮肤，用16号针头刺入腹腔，收集腹水。待腹水再生积聚后，再次收集。将收集的腹水3000 r/min离心10min，取中间澄清部分，用滤纸过滤后，分装，-70℃保存。
1.5 抗体纯化
用Protein-G柱子进行腹水纯化，步骤如下：取腹水2ml（n），10000g离心，取澄清部分，加入2ml（1:1）洗涤缓冲液，混匀，柱子用20%乙醇流尽后用8mL洗涤液平衡，样本过柱子，流速为8S/滴沉，反复上样3次，然后用15mL洗涤缓冲液进行洗涤淀，流速为8S/滴沉，洗涤完毕后用10mL的洗脱缓冲液进行洗脱，洗脱完毕会用1M Tris PH=9调PH至7.4，然后用浓缩注进行浓缩，于50kd透析袋，PBS，4℃透析过夜。
实施例2：鼠抗OXA-48型碳青霉烯酶单克隆抗体的鉴定
2.1 抗体亚类鉴定
按照SIGMA试剂盒说明书，以捕获ELISA的方法进行单抗的亚类鉴定，具体如下：将单抗亚类鉴定试剂1:1000稀释后，加入酶标孔中，100μL/孔，37℃孵育1h；PBST洗三次，拍干；将抗体1:1000倍稀释后加样，100 μL/孔，37℃孵育1h；PBST洗三次，拍干；HRP酶标羊抗鼠IgG二抗以1:6000稀释后加样， 100μL/孔，室温孵育30min；显色10～20min。以OD450读值明显高于其他孔所加亚类试剂为单抗所属亚类类型。抗体IB5的抗体亚型为IgA，IH3的抗体亚型为IgG1。
2.2 抗体效价测定
采用间接ELISA法进行纯化后抗体效价测定，步骤如下： OXA-48碳青霉烯酶分别稀释至0.2ug/mL，100ul/孔，同时设立不包被对照，4℃过夜包被，甩干，PBST洗涤3次；5%脱脂乳粉，200ul/孔，37度封闭2h；甩干，PBST洗涤3次，加入从1:1000倍开始进行倍比稀释的抗体（浓度为1mg/ml），共计12个梯度，同时设立不包被对照100ul/孔， 37℃，1h。甩干，PBST洗涤3次，加 PBS 1:6000倍稀释的羊抗鼠二抗，100ul/孔，37℃，45min。甩干，PBST洗涤5次，加100ulTMB/孔，37℃，显色10min，终止，读值。纯化后抗体稀释至1mg/ml，效价达到了1:1280000以上。
2.3 抗体纯度及分子量鉴定
采用SDS-PAGE法进行抗体分子量及纯度鉴定；制胶，分离胶为12%，浓缩胶为5%；制样，20ul样品+20ul buffer，混匀，煮沸3min；每孔上样20ul，同时设立蛋白预染Marker对照；80伏30min，120伏2h；电泳完毕后，放入考马斯亮蓝溶液进行染色；脱色，去离子水煮沸脱色，每次5min，共计3次；lgG抗体重链的分子质量一般为50-75KDa，lgG抗体轻链的分子量约为25KDa，通过SDS-PAGE对纯化得到的单克隆抗体进行鉴定；如图2所示，抗体IB5和抗体IH3在50-75KDa和约25KDa处均各有清晰的条带。
实施例3：鼠抗OXA-48型碳青霉烯酶单克隆抗体的基因验证
RT-PCR法克隆Ig可变区基因。提取总RNA，合成单链cDNA。
用Trizol法（试剂盒购自Invitrogen）提取IB5、IH3杂交瘤细胞株的总RNA，用M-MLV逆转录酶（购自Invitrogen）将总RNA逆转为cDNA文库。
重链骨架区上游引物
P1：5’SAGGTGMAGCTKCASSARTCWGG3’
重链可变区下游引物
P2：5’TGGGGSTGTYGTTTTGGCTGMRGAGACRGTGA3’
轻链前导肽上游引物
P3：5’ATGGATTTTCAAGTGCAGATTTTCAG3’
轻链可变区下游引物
P4：5’GGATACAGTTGGTGCAGCATCAGCCCGTTT3’
配制PCR反应体系（50μl）如下：
cDNA:2μl；上游引物(10μM):2μl；下游引物(10μM):2μl；dNTP mixture:2μl；pfuDNA聚合酶(5U/μl):1μl；10×pfu Buffer Ⅱ:5μl；ddH2O:补足至50μl。
反应条件：95℃预变性5min；重复如下循环35次：95℃30s，58℃30s，72℃1min；最后，72℃延伸10min。
琼脂糖凝胶电泳分离并回收VL、VH片段。将回收后的VL、VH片段分别与pMD19-T(simple)载体(Takara公司)进行连接，连接体系如下：
VL PCR产物/VH PCR产物各70ng，pMD19-T(simple) 载体1μl，Solution I连接反应液5μl；ddH2O补足至10μl，4℃连接过夜。
连接产物转化入E.coli DH5α感受态细菌中，37℃过夜培养后，挑取单个菌落，37℃震摇2小时后进行菌液PCR鉴定，以对应抗体的cDNA为阳性对照。配制反应体系（25μl）如下：
菌液：1μl，上游引物(10μM)：1μl；下游引物(10 μM) ：1μl；dNTP Mixture (各2.5Mm) 2 μl；Taq DNA聚合酶 (5U/μl)：0.5 μl；10×Taq Buffer (Mg2+ plus)：2.5 μl；补水至25μl。反应条件同前。
选取菌PCR阳性的克隆扩大培养，用质粒提取试剂盒（Takara公司）提取阳性克隆质粒，送检测序。每个抗体的每条链至少送检5个克隆样品，至少三个样品测序结果相同为止。成功克隆得到抗体IB5、IH3的重链、轻链可变区序列，经比对符合典型抗体可变区序列特征。
实施例4：胶体金法制备OXA-48型碳青霉烯酶测卡
制备双抗体夹心法免疫胶体金试纸条，制备方法为：
步骤一向胶体金溶液中边搅拌边加入0.1M K2CO3溶液，调节pH值后加入抗OXA-48型碳青霉烯酶单克隆抗体IH3，搅拌后加入10%的牛血清白蛋白溶液，2%PEG20000，搅拌后低速离心取上清，再高速离心后取沉淀，用胶体金重悬液定容形成金标抗体；
步骤二将金标抗体喷于玻璃纤维素膜，烘干制成金标垫；
步骤三向抗OXA-48型碳青霉烯酶单克隆抗体IB5中加入1%的硫柳汞钠溶液，混匀后形成检测线包被液，再向羊抗鼠IgG中加入PBS和1%的硫柳汞钠溶液，混匀后形成质控线包被液，将质控线包被液和检测线包被液划在硝酸纤维素膜上，烘干后获得包被膜；
步骤四将包被膜贴在底板上，将金标垫和吸水纸搭上包被膜，层压后切割获得胶体金法OXA-48型碳青霉烯酶检测卡。
取通过上述方法制备得到的胶体金法OXA-48型碳青霉烯酶检测卡，分别取空白样、OXA-48型碳青霉烯酶和含有OXA-48型碳青霉烯酶阳性样本点样于检测卡。结果如图3所示，从左到右依次为空白样、OXA-48型碳青霉烯酶和含有OXA-48型碳青霉烯酶阳性样本，能够看出，空白样点样的检测卡检测结果呈阴性，OXA-48型碳青霉烯酶和含有OXA-48型碳青霉烯酶阳性样本点样结果均为阳性，证明通过本方案制备得到的胶体金法OXA-48型碳青霉烯酶检测卡能够检测OXA-48型碳青霉烯酶及相应阳性样本。
以上对本发明的实施例进行了详细说明，但所述内容仅为本发明的较佳实施例，不能被认为用于限定本发明的实施范围。凡依本发明申请范围所作的均等变化与改进等，均应仍归属于本发明的专利涵盖范围之内。
序列表
<110> 天津一瑞生物科技股份有限公司
北京金山川科技股份有限公司
天津喜诺生物医药有限公司
<120> 一种鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用
<130> 2021
<160> 20
<170> SIPOSequenceListing 1.0
<210> 1
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Arg Ala Ser Lys Ser Ile Ser Lys Tyr Leu Ala
1 5 10
<210> 2
<211> 7
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Ser Gly Ser Thr Phe Gln Ser
1 5
<210> 3
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Gln Gln His Asn Glu Tyr Pro Tyr Val Thr
1 5 10
<210> 4
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Gly Phe Thr Phe Ser Thr Tyr Ala Met Ser
1 5 10
<210> 5
<211> 17
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Thr Ile Ser Ser Gly Gly Ser Tyr Thr Ser Tyr Pro Asp Ser Val Lys
1 5 10 15
Gly
<210> 6
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Arg Pro Glu Tyr Ala Met Asp Tyr
1 5
<210> 7
<211> 114
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Asp Trp Ile Gln Leu Val Gln His Gln Pro Val Ser Ser Tyr Leu Ala
1 5 10 15
Ala Ser Pro Gly Glu Thr Val Thr Ile Asn Cys Arg Ala Ser Lys Ser
20 25 30
Ile Ser Lys Tyr Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn
35 40 45
Lys Leu Leu Ile Tyr Ser Gly Ser Thr Phe Gln Ser Gly Phe Pro Ser
50 55 60
Gly Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Val Ser
65 70 75 80
Ser Leu Glu Pro Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln His Asn
85 90 95
Glu Tyr Pro Tyr Val Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Ala
<210> 8
<211> 342
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
gattggatac agttggtgca gcatcagccc gtttcatctt atcttgctgc atctcctgga 60
gaaaccgtta ctattaattg cagggcaagt aagagcatta gcaagtattt agcctggtat 120
caagagaaac ctgggaaaac taataagctt cttatctact ctggttccac tttccaatct 180
ggatttccat cagggttcag tggcagtgga tctggtacag atttcactct caccgtcagt 240
agcctggagc ctgaagactt tgcaatctat tactgtcaac agcataatga gtacccgtac 300
gtcacgttcg gaggggggac caagctggag ataaaacggg ct 342
<210> 9
<211> 120
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 9
Gln Cys Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro
1 5 10 15
Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
20 25 30
Thr Tyr Ala Met Ser Trp Val Arg Leu Thr Pro Glu Lys Arg Leu Glu
35 40 45
Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Ser Tyr Pro Asp
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr
65 70 75 80
Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr
85 90 95
Tyr Cys Ala Arg Arg Pro Glu Tyr Ala Met Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Ser Val Thr Val Ser Ser Ala
115 120
<210> 10
<211> 360
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
cagtgtgaag tgatgctggt ggagtctggg ggaggcttag tgaagcctgg agggtccctg 60
aaactctcct gtgcagcctc tggattcact ttcagtacct atgccatgtc ttgggttcgc 120
ctgactccgg agaagaggct ggagtgggtc gcaaccatta gtagtggtgg tagttacacc 180
tcctatccag acagtgtgaa ggggcgcttc accatctcca gagacaatgc caagaacacc 240
ctgtacctgc aaatgagcag tctgaggtct gaggacacgg ccatgtatta ctgtgcacga 300
cgacccgaat atgctatgga ctactggggt caaggaacct cagtcaccgt ctcctcagcc 360
<210> 11
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His
1 5 10 15
<210> 12
<211> 7
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Leu Val Ser Asn Leu Glu Ser
1 5
<210> 13
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Gln His Ile Arg Glu Leu Tyr Thr
1 5
<210> 14
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Gly Tyr Thr Phe Thr Asp Tyr Val Ile Ser
1 5 10
<210> 15
<211> 17
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 15
Glu Ile Tyr Pro Gly Ser Asp Thr Thr Tyr His Asn Glu Lys Phe Lys
1 5 10 15
Gly
<210> 16
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 16
Asp Tyr Gly Ser Asn Tyr Gly Trp Phe Ala Tyr
1 5 10
<210> 17
<211> 110
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 17
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Gln Arg Ala Thr Ile Ser Tyr Arg Ala Ser Lys Ser Val Ser Thr Ser
20 25 30
Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45
Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65 70 75 80
Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ile Arg
85 90 95
Glu Leu Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 18
<211> 330
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 18
gacattgtgc tgacacagtc tcctgcttcc ttagctgtat ctctggggca gagggccacc 60
atctcataca gggccagcaa aagtgtcagt acatctggct atagttatat gcactggaac 120
caacagaaac caggacagcc acccagactc ctcatctatc ttgtatccaa cctagaatct 180
ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat 240
cctgtggagg aggaggatgc tgcaacctat tactgtcagc acattaggga gctttacacg 300
ttcggagggg ggaccaagct ggaaataaaa 330
<210> 19
<211> 120
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 19
Glu Val Lys Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Met Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Val Ile Ser Trp Val Lys Gln Arg Asn Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Tyr Pro Gly Ser Asp Thr Thr Tyr His Asn Glu Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Ala Asp Ile Ser Ser Asn Thr Val Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Phe Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95
Ala Arg Asp Tyr Gly Ser Asn Tyr Gly Trp Phe Ala Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ala
115 120
<210> 20
<211> 360
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 20
gaggtgaagc tgcagcagtc tggacctgag ttggtgaagc ctggggcttc agtgaagatg 60
tcctgcatgg cttctggata cacattcact gactatgtta taagttgggt gaagcagaga 120
aatggacagg gccttgagtg gattggagag atttatcctg gaagtgatac cacttaccac 180
aatgagaaat tcaagggcaa ggccacactg actgcagaca tatcctccaa cacagtctac 240
atgcagctca gtagtctgac atttgaggat tctgcggtct atttctgtgc aagagactac 300
ggtagtaact acggctggtt tgcttactgg ggccaaggga ctctggtcac tgtctctgca 360
Claims (9)
1.一种鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株，其特征在于：命名为IB5，保藏编号为CGMCC No.20284；或者命名为IH3，保藏编号为CGMCC No.20283。
2.一种鼠抗OXA-48型碳青霉烯酶抗体，其特征在于：抗体IB5，包括轻链可变区和重链可变区，轻链可变区包括如SEQ ID NO:1所示的CDRL1、SEQ ID NO:2所示的CDRL2和SEQ IDNO:3所示的CDRL3，重链可变区包括如SEQ ID NO:4所示的CDRH1、SEQ ID NO:5所示的CDRH2和SEQ ID NO:6所示的CDRH3；
或者，
抗体IH3，轻链可变区包括如SEQ ID NO:11所示的CDRL1、SEQ ID NO:12所示的CDRL2和SEQ ID NO:13所示的CDRL3，重链可变区包括如SEQ ID NO:14所示的CDRH1、SEQ ID NO:15所示的CDRH2和SEQ ID NO:16所示的CDRH3。
3.根据权利要求2所述的鼠抗OXA-48型碳青霉烯酶抗体，其特征在于：抗体IB5轻链可变区氨基酸序列为SEQ ID NO:7所示，重链可变区氨基酸序列为SEQ ID NO:9所示；
或者，
抗体IH3轻链可变区氨基酸序列为SEQ ID NO:17所示，重链可变区氨基酸序列为SEQID NO:19所示。
4.根据权利要求2或3所述的鼠抗OXA-48型碳青霉烯酶抗体，其特征在于：抗体IB5由保藏编号为CGMCC No.20284的鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株产生；
抗体IH3由保藏编号为CGMCC No.20283的鼠抗OXA-48型碳青霉烯酶杂交瘤细胞株产生。
5.一种核酸分子，其特征在于：包含编码权利要求2或3所述的鼠抗OXA-48型碳青霉烯酶抗体的核苷酸。
6.根据权利要求5所述的核酸分子，其特征在于：所述核酸分子编码抗体IB5的轻链可变区的核苷酸序列如SEQ ID NO:8所示，所述核酸分子编码抗体IB5的重链可变区的核苷酸序列如SEQ ID NO:10所示；
或者，
所述核酸分子编码抗体IH3的轻链可变区的核苷酸序列如SEQ ID NO:18所示，所述核酸分子编码抗体IH3的重链可变区的核苷酸序列如SEQ ID NO:20所示。
7.权利要求2-4中任一所述的鼠抗OXA-48型碳青霉烯酶抗体在制备检测OXA-48型碳青霉烯酶抗原试剂中的应用。
8.根据权利要求7所述的鼠抗OXA-48型碳青霉烯酶抗体在制备检测OXA-48型碳青霉烯酶抗原试剂中的应用，其特征在于：将鼠抗OXA-48型碳青霉烯酶抗体用于制备体外诊断试剂盒或微流体芯片，所述体外诊断试剂盒为胶体金免疫试剂盒、化学发光试剂盒、放射免疫试剂盒、酶联免疫试剂盒或荧光免疫试剂盒。
9.根据权利要求7所述的鼠抗OXA-48型碳青霉烯酶抗体在制备检测OXA-48型碳青霉烯酶抗原试剂中的应用，其特征在于：制备双抗体夹心法免疫胶体金试纸条，抗体IB5为包被抗体，抗体IH3为金标抗体；
或者，抗体IH3为包被抗体，抗体IB5为金标抗体。
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210189253.2A CN114317454B (zh) | 2022-03-01 | 2022-03-01 | 一种鼠抗oxa-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
| PCT/CN2022/141242 WO2023165229A1 (zh) | 2022-03-01 | 2022-12-23 | 一种鼠抗oxa-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
| EP22871058.8A EP4261227A4 (en) | 2022-03-01 | 2022-12-23 | ANTI-OXACILLINASE-48-LIKE (OXA-48-LIKE) CARBAPENEMASE MOUSE HYBRIDOMA CELL LINE, MONOCLONAL ANTIBODY AND APPLICATION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210189253.2A CN114317454B (zh) | 2022-03-01 | 2022-03-01 | 一种鼠抗oxa-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114317454A CN114317454A (zh) | 2022-04-12 |
| CN114317454B true CN114317454B (zh) | 2023-10-03 |
Family
ID=81029914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210189253.2A Active CN114317454B (zh) | 2022-03-01 | 2022-03-01 | 一种鼠抗oxa-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4261227A4 (zh) |
| CN (1) | CN114317454B (zh) |
| WO (1) | WO2023165229A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114317454B (zh) * | 2022-03-01 | 2023-10-03 | 天津一瑞生物科技股份有限公司 | 一种鼠抗oxa-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
| CN114755420B (zh) * | 2022-05-30 | 2023-02-03 | 广东聚诚生物技术有限公司 | 碳青霉烯酶联合检测试剂盒 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007053999A (ja) * | 2005-08-25 | 2007-03-08 | Univ Nihon | 抗ｇｔｆ抗体及びその製造方法 |
| WO2016092096A1 (en) * | 2014-12-11 | 2016-06-16 | ALERE TECHNOLOGIES GmbH | Anti-carbapenemase antibodies and uses thereof |
| WO2016162564A1 (en) * | 2015-04-10 | 2016-10-13 | Coris Bioconcept Sprl | Method and device for detecting a carbapenemase-producing enterobacteriaceae |
| CN107759699A (zh) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | 靶向cd30抗原的转基因t细胞及其制备方法与应用 |
| CN108530536A (zh) * | 2018-03-27 | 2018-09-14 | 刘爽 | Cart-cd123及其制备与应用 |
| CN109923129A (zh) * | 2016-08-26 | 2019-06-21 | 新加坡科技研究局 | 巨噬细胞刺激蛋白受体（或RON-Recepteur d,Origine Nantais）抗体及其用途 |
| CN112980804A (zh) * | 2021-05-12 | 2021-06-18 | 天津一瑞生物科技股份有限公司 | 一种抗kpc型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020016814A1 (en) * | 2018-07-20 | 2020-01-23 | UNIVERSITé LAVAL | Nucleic acid-based detection of carbapenemase-producing bacteria |
| CN112501131B (zh) * | 2021-02-07 | 2021-05-04 | 天津一瑞生物科技股份有限公司 | 抗imp型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
| CN112500489B (zh) * | 2021-02-07 | 2021-05-04 | 天津一瑞生物科技股份有限公司 | 一种抗oxa-23型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
| CN112980803B (zh) * | 2021-05-12 | 2021-07-30 | 天津一瑞生物科技股份有限公司 | 抗vim型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
| CN114317454B (zh) * | 2022-03-01 | 2023-10-03 | 天津一瑞生物科技股份有限公司 | 一种鼠抗oxa-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
-
2022
- 2022-03-01 CN CN202210189253.2A patent/CN114317454B/zh active Active
- 2022-12-23 WO PCT/CN2022/141242 patent/WO2023165229A1/zh unknown
- 2022-12-23 EP EP22871058.8A patent/EP4261227A4/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007053999A (ja) * | 2005-08-25 | 2007-03-08 | Univ Nihon | 抗ｇｔｆ抗体及びその製造方法 |
| WO2016092096A1 (en) * | 2014-12-11 | 2016-06-16 | ALERE TECHNOLOGIES GmbH | Anti-carbapenemase antibodies and uses thereof |
| WO2016162564A1 (en) * | 2015-04-10 | 2016-10-13 | Coris Bioconcept Sprl | Method and device for detecting a carbapenemase-producing enterobacteriaceae |
| CN109923129A (zh) * | 2016-08-26 | 2019-06-21 | 新加坡科技研究局 | 巨噬细胞刺激蛋白受体（或RON-Recepteur d,Origine Nantais）抗体及其用途 |
| CN107759699A (zh) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | 靶向cd30抗原的转基因t细胞及其制备方法与应用 |
| CN108530536A (zh) * | 2018-03-27 | 2018-09-14 | 刘爽 | Cart-cd123及其制备与应用 |
| CN112980804A (zh) * | 2021-05-12 | 2021-06-18 | 天津一瑞生物科技股份有限公司 | 一种抗kpc型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
Non-Patent Citations (5)
| Title |
|---|
| "anti-CD22 scFv-gelonin antibody [synthetic construct]";Tran 等;《GenBank Database》;Accession NO：AGO85913.1 * |
| "anti-DNA quadruplex antibody kappa light chain variable region, partial [Mus musculus]";Brown 等;《GenBank Database》;Accession NO：AAC35991.1 * |
| "Evaluation of two new commercial immunochromatographic assays for the rapid detection of OXA-48 and KPC carbapenemases from cultured bacteria";Glupczynski 等;《JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY》;第71卷(第5期);1217-1222 * |
| "Targeting Anti-Insulin B Cell Receptors Improves Receptor Editing in Type 1 Diabetes-Prone Mice";Bonami 等;《J Immunol》;第195卷(第10期);4730-41 * |
| "产KPC型碳青霉烯酶肺炎克雷伯菌的检测及感染现状";刘希华;《中国实验诊断学》;第21卷(第2期);225-227 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114317454A (zh) | 2022-04-12 |
| EP4261227A4 (en) | 2024-05-01 |
| EP4261227A1 (en) | 2023-10-18 |
| WO2023165229A1 (zh) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112500489B (zh) | 一种抗oxa-23型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 | |
| CN112501131B (zh) | 抗imp型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 | |
| CN112980803B (zh) | 抗vim型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 | |
| CN114317454B (zh) | 一种鼠抗oxa-48型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 | |
| CN112980804B (zh) | 一种抗kpc型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 | |
| CN113416710B (zh) | 一种鼠抗mcr-1蛋白杂交瘤细胞株，单克隆抗体及应用 | |
| EP4265717A1 (en) | Mouse anti-mcr-1/mcr-2 protein hybridoma cell strain, monoclonal antibody and use | |
| CN109438576B (zh) | 一种抗人cd47单克隆抗体的制备及其应用 | |
| CN116042532A (zh) | 一种鼠抗ndm型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 | |
| CN113912710B (zh) | 抗新型冠状病毒n蛋白的单克隆抗体及其应用 | |
| CN114317455B (zh) | 鼠抗mcr-1蛋白杂交瘤细胞株，单克隆抗体及应用 | |
| CN117050183B (zh) | 一种ptn-ptprz1通路的阻断抗体及其在胶质瘤靶向治疗的应用 | |
| CN116462758B (zh) | 抗人ptprz1单克隆抗体及其在细胞流式中的应用 | |
| CN116769040B (zh) | 鼠抗gdh杂交瘤细胞株，单克隆抗体及应用 | |
| CN116769023B (zh) | 鼠抗马尔尼菲篮状菌甘露聚糖蛋白杂交瘤细胞株，单克隆抗体及应用 | |
| CN116970082B (zh) | 人源cd7单克隆抗体及其制备方法和应用 | |
| CN115304670A (zh) | 一种猫冠状病毒核衣壳蛋白的鼠源单克隆抗体及其编码基因和应用 | |
| CN116948032A (zh) | 人源cd4单克隆抗体及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |